US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

US President Donald Trump has signed an executive order that aims to reduce high prescription drug prices – but its details ...

European pharma leaders push for higher drug prices to boost global competitiveness. 2. CEOs warn EU may lose out on ...

An assessment by UBS says Bristol Myers Squibb and Pfizer would be worst hit among US companies if Mr Trump’s threatened ...

This sharp decline comes amid broader market volatility and specific concerns in the healthcare sector, particularly related to pricing pressures and regulatory scrutiny surrounding weight-loss drugs, ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Novo Nordisk and Eli Lilly , the leaders in the highly lucrative ... Roche says Trump's drug price order threatens its $50 billion US investment plans U.S. President Donald Trump's executive ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say. J&J, Eli Lilly, Pfizer, Merck, Amgen are included in ...

Novo Nordisk has replaced CEO Lars Fruergaard Jorgensen amid competitive pressures in the obesity drug market. His exit comes ...

Eli Lilly (LLY) shares take a dip after Politico reports that President Trump will sign a new executive order around drug ...

The discontinuation rate due to side effects was 6.1% for Zepbound and 8% for ... saying it would align US drug prices with the lowest-paying country. Eli Lilly’s stock has declined 5.6% so far in ...